Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Red Light Treatment in Peripheral Artery Disease

NCT: NCT03203239 · RECRUITING

NCT IDNCT03203239
StatusRECRUITING
Start Date2018-01-17
Completion2028-12-31

Brief Summary

Subjects with a known diagnosis of peripheral artery disease as measured by an abnormal ankle brachial index (\<.9 or \>1.1) will undergo a single 5 min exposure of 670 nm light, 1 cm above the gastrocnemius muscle. Blood flow will be measured by infusion of ultrasound contrast and subsequent acquisition of ultrasound images. 2 blood samples will be collected for measurement of nitric oxide metabolites.

Frequently Asked Questions

What is Red Light Treatment in Peripheral Artery Disease?

Red Light Treatment in Peripheral Artery Disease is a clinical trial registered under NCT03203239. Current status: RECRUITING.

What is the status of NCT03203239?

The current status of NCT03203239 (Red Light Treatment in Peripheral Artery Disease) is: RECRUITING.

When did Red Light Treatment in Peripheral Artery Disease start?

Red Light Treatment in Peripheral Artery Disease started on 2018-01-17.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.